Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
217 stopped studies mapped to Pancreatic Carcinoma and descendants · 94% state a reason
Over the 217 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | University Medical Center Groningen | Insufficient tumor-to-background ratios in the first three dose groups | Other (stated, no rule matched) |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | Phase 1 | withdrawn | Mar 7, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | We need to make significant adjustments to proposed drug and its delivery method | Other (stated, no rule matched) |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for… | Phase 1 / Phase 2 | terminated | Sep 12, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study was terminated due to cease in manufacturing of study drug. | Drug supply |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic… | Phase 2 | withdrawn | Aug 5, 2008 | University of Cincinnati | study withdrawn due to lack of enrollment | Enrollment / accrual |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced…(LAPC-BC-819) | Phase 2 | terminated | Aug 10, 2011 | Anchiano Therapeutics Israel Ltd. | Due to Sponsor's decision, only 12 patients were randomized \& completed study. | Sponsor / business decision |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | terminated | Dec 28, 2006 | National Cancer Institute (NCI) | Study was terminated due to poor accrual | Enrollment / accrual |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and… | Phase 2 | withdrawn | Oct 17, 2019 | Indiana University | Study is being abandoned. | Other (stated, no rule matched) |
| NCT02885727 | Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post…(Panc-Durval+RT) | Phase 2 | withdrawn | Aug 31, 2016 | University of Maryland, Baltimore | Funding issues caused the study to not be opened the at local IRB | Funding |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | terminated | Feb 2, 2015 | Washington University School of Medicine | Insufficient funding and drug supply from manufacturer | Drug supply |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic… | Early Phase 1 | terminated | Mar 29, 2018 | PH Research, S.L. | Stopped Enrollment | Enrollment / accrual |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With… | Phase 1 | terminated | Mar 14, 2016 | The Cooper Health System | Closed after being on administrative hold | Other (stated, no rule matched) |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance… | Phase 1 | terminated | Dec 3, 2012 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02404363 | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic…(PANCREADOGREL) | Phase 3 | terminated | Mar 31, 2015 | Assistance Publique - Hôpitaux de Paris | recruitment problem | Enrollment / accrual |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or… | Phase 1 / Phase 2 | withdrawn | Dec 19, 2018 | Alan Katz | CCX872-B will not be available in sufficient quantity to conduct the study. | Other (stated, no rule matched) |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | Phase 2 | terminated | Apr 28, 2014 | CCTU- Cancer Theme | Poor accrual | Enrollment / accrual |
| NCT01313416 | Gemcitabine and CT-011 for Resected Pancreatic Cancer | Phase 2 | terminated | Mar 11, 2011 | Augusta University | Drug supply issues | Drug supply |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients… | Phase 2 | terminated | Apr 13, 2016 | Eben Rosenthal | Logistics | Other (stated, no rule matched) |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin +… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2018 | Hitendra Patel | FDA indicated the same study could not be conducted under multiple INDs | Other (stated, no rule matched) |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | Phase 2 | withdrawn | Feb 14, 2018 | M.D. Anderson Cancer Center | Incyte (supporter of the study) is no longer going to support the study. | Other (stated, no rule matched) |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and… | Phase 1 / Phase 2 | withdrawn | Apr 9, 2019 | Medical College of Wisconsin | Request to close per funding sponsor. Site not moving forward with trial. | Funding |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary… | Phase 2 | terminated | Oct 31, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot… | Phase 1 | terminated | May 25, 2016 | University of Chicago | Closed early due to poor accrual. | Enrollment / accrual |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | Phase 2 | terminated | Jan 4, 2013 | Beth Israel Medical Center | not stated | Not stated |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line… | Phase 2 | terminated | Dec 2, 2011 | University Health Network, Toronto | not stated | Not stated |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally… | Phase 4 | withdrawn | Oct 7, 2015 | Yonsei University | Investigator decided to stop the study because it was difficult to proceed with the study. | Investigator |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and… | Phase 2 | terminated | Aug 13, 2013 | Radiation Therapy Oncology Group | Trial would not be completed in a reasonable timeframe per CTEP guidelines | Other (stated, no rule matched) |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | Phase 2 | terminated | Jan 26, 2015 | Case Comprehensive Cancer Center | Competing studies | Other (stated, no rule matched) |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | Phase 2 | terminated | May 24, 2011 | University of Oklahoma | The principal investigator terminated the study due to inactivity and low enrollment | Investigator |
| NCT02496832 | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With… | N/A | withdrawn | Jul 14, 2015 | University Health Network, Toronto | Study was never initiated | Other (stated, no rule matched) |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Massachusetts General Hospital | Funding was withdrawn after only 10 participants were enrolled | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With… | Phase 1 / Phase 2 | terminated | May 22, 2009 | Cornerstone Pharmaceuticals | Suspended trial was not restarted. | Other (stated, no rule matched) |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT01888965 | Maintenance Dovitinib for Colorectal and Pancreas Cancer | Phase 2 | terminated | Jun 28, 2013 | Georgetown University | Adverse Event issues. | Safety / toxicity |
| NCT01784081 | Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients…(iPC3) | — | withdrawn | Feb 5, 2013 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | study was closed by PI due to no accrual | Enrollment / accrual |
| NCT01911416 | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog… | N/A | withdrawn | Jul 30, 2013 | University of Utah | No accrual | Enrollment / accrual |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Oct 14, 2015 | Roswell Park Cancer Institute | drug supply issues | Drug supply |
| NCT01814631 | Endoscopic Ultrasound (EUS) Processor Comparison | — | withdrawn | Mar 20, 2013 | AdventHealth | Closed at PI discretion | Other (stated, no rule matched) |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | Early Phase 1 | terminated | Oct 14, 2013 | University of Virginia | From preliminary imaging data, the study was stopped due to futility. | Efficacy / futility |
| NCT00843830 | A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed… | Phase 1 | terminated | Feb 13, 2009 | University of Michigan Rogel Cancer Center | Study closed early secondary to inability to obtain grant funding to conduct. | Funding |
| NCT00864513 | Study of Pemetrexed for Second-Line Pancreas Cancer | Phase 2 | terminated | Mar 18, 2009 | Georgetown University | At interim analysis the study did not meet the response criteria to continue | Efficacy / futility |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | Phase 2 | withdrawn | Sep 28, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT00598091 | A Phase I/Expansion Study of Dasatinib(Gem/Dsat) | Phase 1 | terminated | Jan 18, 2008 | Duke University | Low accrual, unable to meet endpoint in timely manner | Enrollment / accrual |
| NCT01419002 | Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in…(Net-Pac) | Phase 3 | terminated | Aug 17, 2011 | CHIR-Net | lack of recruitment | Enrollment / accrual |
| NCT01050283 | A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With… | Phase 1 | terminated | Jan 15, 2010 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are… | Phase 2 | withdrawn | Nov 15, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 28, 2020source: clinicaltrials